Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 4Unknown 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Myeloid 2

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Mast Cell Activation Disorders × Clear all
NCT04615663 2020-11-04

MCD&BuDi

University Hospital, Toulouse

Unknown
200 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis

NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 2/3 Unknown
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡